Cheryl Fitzer-Attas

Citado por

	Total	Desde 2019
Citas	3808	1278
Índice h	28	17
Índice i10	37	25

280

140

210

1990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420 28 27 21 39 30 25 27 59 74 76 86 78 67 65 65 87 79 65 108 106 138 155 153 151 147 149 181 169 165 208 277 278 268 78

Acceso público

Ver todo

4 artículos

5 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Robert HauserProfessor of Neurology, University of South FloridaDirección de correo verificada de health.usf.edu
Olivier RASCOLUT3 Professor, CHU Purpan, Tonic (INSERM-UT3), CIC 1436 (INSERM-CHU-UT3), TMBI (Univ. Toulouse)Dirección de correo verificada de univ-tlse3.fr
Julie C. StoutProfessor, School of Psychological Science, Monash University, Victoria, AustraliaDirección de correo verificada de monash.edu
Anthony L. DeFrancoProfessor of Microbiology and Immunology, University of California, San FranciscoDirección de correo verificada de ucsf.edu
Clifford LowellProfessor, University of California, San FranciscoDirección de correo verificada de ucsf.edu
Daniel SchindlerScientist at IgCDirección de correo verificada de igc.bio
Patrik FazioKarolinska InstitutetDirección de correo verificada de ki.se
Joseph GiulianoAmicus Therapeutics, IncDirección de correo verificada de amicusrx.com
Alan GodfreyAssociate Professor (Reader), Northumbria UniversityDirección de correo verificada de northumbria.ac.uk
Jessie P BakkerLecturer in Medicine; Brigham & Women's Hospital and Harvard Medical SchoolDirección de correo verificada de bwh.harvard.edu
Benjamin VandendriesscheCase Western Reserve UniversityDirección de correo verificada de case.edu
Werner PoeweProfessor NeurologieDirección de correo verificada de i-med.ac.at
Anthony E LangUniversity of TorontoDirección de correo verificada de uhnres.utoronto.ca
Warren OlanowMount Sinai School of MedicineDirección de correo verificada de clintrex.com
Elena IzmailovaCSO, Koneksa HealthDirección de correo verificada de koneksahealth.com
Martin TurnerThe Babraham Institute, Cambridge, CB22 3AT, UK.Dirección de correo verificada de babraham.ac.uk
Victor TybulewiczFrancis Crick InstituteDirección de correo verificada de crick.ac.uk
Joaquim FerreiraFaculdade de Medicina, Universidade de LisboaDirección de correo verificada de medicina.ulisboa.pt
Michael HaydenKillam Professor, University of British ColumbiaDirección de correo verificada de cmmt.ubc.ca
Karen Elta AndersonGeorgetown UniversityDirección de correo verificada de georgetown.edu

Seguir

Cheryl Fitzer-Attas

ClinMed LLC

Dirección de correo verificada de clinmedaffairs.com - Página principal

Clinical and Medical Affairs Business Development Communications


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages MT Crowley, PS Costello, CJ Fitzer-Attas, M Turner, F Meng, C Lowell, ... Journal of Experimental Medicine 186 (7), 1027-1039, 1997	654	1997
Fcγ receptor–mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn CJ Fitzer-Attas, M Lowry, MT Crowley, AJ Finn, F Meng, AL DeFranco, ... Journal of Experimental Medicine 191 (4), 669-682, 2000	324	2000
Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs) JC Goldsack, A Coravos, JP Bakker, B Bent, AV Dowling, C Fitzer-Attas, ... npj digital Medicine 3 (1), 55, 2020	275	2020
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in … O Rascol, CJ Fitzer-Attas, R Hauser, J Jankovic, A Lang, JW Langston, ... The Lancet Neurology 10 (5), 415-423, 2011	265	2011
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives EM Sigurdsson, E Knudsen, A Asuni, C Fitzer-Attas, D Sage, ... Journal of Neuroscience 24 (28), 6277-6282, 2004	191	2004
Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease RA Hauser, MF Lew, HI Hurtig, WG Ondo, J Wojcieszek, CJ Fitzer‐Attas, ... Movement Disorders 24 (4), 564-573, 2009	182	2009
Altered levels of protein kinase C and Ca2+-dependent protein kinases in human colon carcinomas JG Guillem, CA O'Brian, CJ Fitzer, KA Forde, P LoGerfo, M Treat, ... Cancer research 47 (8), 2036-2039, 1987	171	1987
Data Analytics from Enroll‐HD, a Global Clinical Research Platform for Huntington's Disease GB Landwehrmeyer, CJ Fitzer‐Attas, JD Giuliano, N Gonçalves, ... Movement Disorders Clinical Practice 4 (2), 212-224, 2017	160	2017
The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several structurally related bile acids CJ Fitzer, CA O'Brian, JG Guillem, IB Weinstein Carcinogenesis 8 (2), 217-220, 1987	132	1987
Increased melanoma risk in Parkinson disease: a prospective clinicopathological study JM Bertoni, JP Arlette, HH Fernandez, C Fitzer-Attas, K Frei, MN Hassan, ... Archives of neurology 67 (3), 347-352, 2010	131	2010
Increased melanoma risk in Parkinson disease: a prospective clinicopathological study JM Bertoni, JP Arlette, HH Fernandez, C Fitzer-Attas, K Frei, MN Hassan, ... Archives of neurology 67 (3), 347-352, 2010	131	2010
Mechanisms compensating for dopamine loss in early Parkinson disease J Brotchie, C Fitzer-Attas Neurology 72 (7 Supplement 2), S32-S38, 2009	119	2009
The T-body approach: potential for cancer immunotherapy Z Eshhar, N Bach, CJ Fitzer-Attas, G Grosse, J Lustgarten, T Waks, ... Springer seminars in immunopathology 18, 199-209, 1996	105	1996
HD‐CAB: A cognitive assessment battery for clinical trials in Huntington's disease^1,2,3 JC Stout, S Queller, KN Baker, S Cowlishaw, C Sampaio, C Fitzer‐Attas, ... Movement Disorders 29 (10), 1281-1288, 2014	103	2014
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial W Poewe, K Seppi, CJ Fitzer-Attas, GK Wenning, S Gilman, PA Low, ... The Lancet Neurology 14 (2), 145-152, 2015	95	2015
Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation CJ Fitzer-Attas, DG Schindler, T Waks, Z Eshhar The Journal of Immunology 160 (1), 145-154, 1998	88	1998
Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study M Masellis, S Collinson, N Freeman, M Tampakeras, J Levy, A Tchelet, ... Brain 139 (7), 2050-2062, 2016	67	2016
Studies on protein kinase C and colon carcinogenesis JG Guillem, CA O'Brian, CJ Fitzer, MD Johnson, KA Forde, P LoGerfo, ... Archives of Surgery 122 (12), 1475-1478, 1987	56	1987
Long‐term effects of rasagiline and the natural history of treated Parkinson's disease O Rascol, RA Hauser, F Stocchi, CJ Fitzer‐Attas, Y Sidi, V Abler, ... Movement Disorders 31 (10), 1489-1496, 2016	54	2016
Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation CJ Fitzer-Attas, DG Schindler, T Waks, Z Eshhar Journal of Biological Chemistry 272 (13), 8551-8557, 1997	45	1997

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores